4

6

3

- 1 A process for the preparation of a nonracemic diastereomer selected
- 2 from 1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds of

. 7

3 the structural formula I and stereoisomers thereof,

wherein R is selected from hydrogen and hydroxyl protecting groups, comprising


hydrogenating a corresponding nonracemic ketone selected from 1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanone compounds of the structural formula II and enantiomers thereof,

Ι

II

in the presence of a catalyst system comprising ruthenium, a nonracemic diphosphine ligand, a bidentate amine ligand selected from amino-thioethers and achiral diamines, and a base.

- The process of claim 1 wherein the nonracemic diphosphine ligand comprises a 2,2'-bis(diorganophosphino)-1,1'-bis(cyclic) structure.
- The process of claim 2 wherein the nonracemic diphosphine ligand is selected from enantiomers of diphosphine ligands having the structural formula



4 wherein Ar is an aryl group.

1	' \	4.	The process of claim 3 wherein Ar is phenyl.	
1	•	5.	The process of claim 1 wherein the bidentate amine ligand is an amino-	
2	thioether.	\		
1		6.	The process of claim 5 wherein the amino-thioether is a	
2	2-(alkylthio)ar	niline.		
1		7.	The process of claim 6 wherein the 2-(alkylthio)aniline is selected	
2	from 2-(methylthio)aniline and 2-(ethylthio)aniline.			
1		8.	The process of claim 1 wherein the bidentate amine ligand is an achiral	
2	diamine.			
<u> </u>		9.	The process of claim 8 wherein the achiral diamine comprises no chiral	
<u>ធ</u> 2 បា	carbon centers.			
1 02 5 1 1 1 1 1		10.	The process of claim 8 wherein the achiral diamine is a 1,2-phenylene-	
№ ጠ	diamine.			
<u> </u>		11.	The process of claim 1 wherein the base is selected from basic	
□1 =2 =================================	inorganic and organic salts, alkylguanidines, aminophosphazenes, and proazaphosphatranes.			
T 1		12 .	The process of claim 11 wherein the base is selected from	
2	alkylguanidines, aminophosphazenes, and proazaphosphatranes.			
1		13.	The process of claim 12 wherein the base is an alkylguanidine.	
1		14.	The process of claim 13 wherein the base is a pentaalkylguanidine.	
. 1		15.	The process of claim 1 wherein the hydroxyl protecting group is	
2	benzyl.			
1		16.	The process of claim 15 wherein the diastereomer is a syn-	
2	diastereomer.			
1		17.	The process of claim 16 wherein the syn -diastereomer is the $(1S,2S)$	
2	diastereomer.			

1	18. The process of claim 16 wherein the syn-diastereomer is formed in at
2	least about 90% diastereomeric excess.
1	19. A process for the preparation of $(1S,2S)-1-(4-benzoxy-phenyl)-2-(4-benzoxy-phenyl)$
2	hydroxy-4-phenyl-piperidin-1-yl)-1- by catalytic hydrogenation of (2S)-1-(4-benzyl-phenyl)-
3	2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanone using a catalyst system comprising
4	ruthenium, a (S,S,S,S)-2,2'-bis-(diarylphosphino)-1,1'-dicyclopentane ligand, a 1,2-phenylene
5	diamine ligand, and a base.
1	20. A process for the preparation of $(1S,2S)-1-(4-benzoxy-phenyl)-2-(4-benzoxy-phenyl)$
2	hydroxy-4-phenyl-piperidin-1-yl)-1- by catalytic hydrogenation of (2S)-1-(4-benzyl-phenyl)-
3	2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanone using a catalyst system comprising
4	ruthenium, a (S,S,S,S)-2,2'-bis-(diarylphosphino)-1,1'-dicyclopentane ligand, a
5	2-(alkylthio)aniline ligand, and a base.